FIBICO –Method to predict the response of the Crohn's disease patient to anti-TFN-alpha therapy

Abstract

A research group from the Andalusian Public Health System (SSPA) has developed an invention within the field of autoimmune diseases, such as Crohn's disease (CD). Focusing on the individualized prognosis of the effectiveness of the treatment with inhibitors of tumor necrosis factor alpha (anti-TFN-alpha) applied in said disease.

Description

CD is a chronic inflammatory bowel disease (IBD) that results from an abnormal immune response to enteric microbes in genetically predisposed individuals, and can affect any location in the Gastrointestinal tract.

Classic CD therapy consists of different combinations of corticosteroids, immunosuppressive agents, and in some cases surgery. The use of anti-TFN-alpha agents improves the quality of life in patients with inflammatory bowel diseases, but their efficacy in patients with Crohn's disease is highly heterogeneous. In addition, their chronic use is expensive and carries a significant risk of infections and other disorders

The present invention focuses on identifying reliable biomarkers to predict the response to treatment with anti-TFN-alpha drugs in patients with CD, which would allow a more efficient prescription of these drugs, thus optimizing the indications and minimizing side effects and costs.

In addition, the method allows us to assess the predictive capacity of the response in both the short (12 weeks) and long (12 months) term.

The object of the invention, therefore, proposes a method to predict the response of Crohn's disease patients to anti-TFN-alpha therapy based on vinculin plasma levels together with the Crohn's Disease Activity Index (CDAI), corticosteroid induction and bowel resection.

Advantage

-More efficient drug prescription: indications are optimized and side effects and costs are minimized.

-Rapid response: the present invention allows knowing results on the response to treatment within a period of 12 weeks.

Industrial/Intellectual protection

This technology is protected by national patent.

Objective of the Collaboration

Seek a collaboration that leads to the commercial exploitation of the invention presented. The terms and conditions of the license agreement can be discussed openly if the technology presented is of interest

Clasification

Activity/Type: Autoimmune diseases.
Pathology: Crohn's disease.

Representative Institution and Inventor

The main investigator behind the innovation is Gustavo Ferrín Sánchez, a researcher in the group GC02 Oxidative and nitrosative stress in acute and chronic liver diseases.

The development of the project has been possible thanks to the Andalusian Health Service, the University of Córdoba and the Consortium Center for Biomedical Research in the Ciber Network

Contact

Fundación para la Investigación Biomédica de Córdoba (FIBICO)

Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Córdoba

Luis M. Fernández Formoso | Head of Unit – Innovation and Technology Transfer: luism.fernandez@imibic.org